Successful Treatment of Disseminated Disease Due to Highly Resistant Aspergillus Calidoustus with a Novel Antifungal Therapy

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Dec 21

PMID 34930032

Citations 6

Authors

Jose F Camargo

Raed Jabr

Anthony D Anderson

Lazaros Lekakis

Meilin Diaz-Paez

Laurence M Briski

Mohammed Raja

Michele I Morris

Krishna V Komanduri

Denise Pereira

Affiliations

Soon will be listed here.

Abstract

Invasive aspergillosis is the most common invasive mold infection following a hematopoietic cell transplant. Widespread use of antifungal prophylaxis has led to the increasing incidence of cryptic Aspergillus species. Aspergillus calidoustus is one of those emerging species and is notorious for multidrug resistance to antifungals. Here, we report a case of disseminated A. calidoustus infection in a hematopoietic stem cell transplant recipient who was successfully treated with combination therapy that included a novel antifungal.

Citing Articles

Invasive Aspergillosis in the Intensive Care Unit.

Zubovskaia A, Vazquez J J Fungi (Basel). 2025; 11(1.

PMID: 39852489 PMC: 11766804. DOI: 10.3390/jof11010070.

Genome-Wide Exploration of Thiamin Pyrophosphate Riboswitches in Medically Relevant Fungi Reveals Diverse Distribution and Implications for Antimicrobial Drug Targeting.

Vargas-Junior V, Guimaraes A, Caffarena E, Antunes D ACS Omega. 2025; 9(51):50134-50146.

PMID: 39741832 PMC: 11683625. DOI: 10.1021/acsomega.4c00158.

Aspergillus calidoustus and Talaromyces columbinus infections in chronic graft-versus-host disease.

Pacini E, Schelenz S, Abdolrasouli A, Mehra V, Ceesay M, Pagliuca A Ann Hematol. 2024; 103(11):4797-4800.

PMID: 39227451 PMC: 11534989. DOI: 10.1007/s00277-024-05980-w.

A Case of Aspergillus calidoustus Thoracic Spine Osteomyelitis.

Okoroafor C, Suryadevara M, Gaba P, Jen P Cureus. 2024; 16(7):e65667.

PMID: 39205705 PMC: 11354405. DOI: 10.7759/cureus.65667.

Fosmanogepix: The Novel Anti-Fungal Agent's Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials.

Almajid A, Bazroon A, Al-Awami H, Albarbari H, Alqahtani I, Almutairi R Cureus. 2024; 16(4):e59210.

PMID: 38807795 PMC: 11131969. DOI: 10.7759/cureus.59210.

References

Lamoth F, Kontoyiannis D . Therapeutic Challenges of Non- Invasive Mold Infections in Immunosuppressed Patients. Antimicrob Agents Chemother. 2019; 63(11). PMC: 6811444. DOI: 10.1128/AAC.01244-19. View

Glampedakis E, Cassaing S, Fekkar A, Dannaoui E, Bougnoux M, Bretagne S . Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study. Clin Infect Dis. 2020; 72(8):1379-1385. DOI: 10.1093/cid/ciaa230. View

Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J . Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009; 48(3):265-73. DOI: 10.1086/595846. View

Yamamuro R, Kimura M, Asano-Mori Y, Abe M, Nakamura S, Umeyama T . Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Antimicrob Agents Chemother. 2021; 66(1):e0163021. PMC: 8765323. DOI: 10.1128/AAC.01630-21. View

Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely O, Krause R . The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs. 2021; 81(15):1703-1729. PMC: 8501344. DOI: 10.1007/s40265-021-01611-0. View

Steinbach W, Marr K, Anaissie E, Azie N, Quan S, Meier-Kriesche H . Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012; 65(5):453-64. DOI: 10.1016/j.jinf.2012.08.003. View

Mendoza M, Anderson A, Morris M, Lekakis L, Simkins J, Prado C . Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient. Mycopathologia. 2020; 185(2):399-403. DOI: 10.1007/s11046-019-00423-x. View

Kontoyiannis D, Marr K, Park B, Alexander B, Anaissie E, Walsh T . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50(8):1091-100. DOI: 10.1086/651263. View

Pavie J, Lacroix C, Hermoso D, Robin M, Ferry C, Bergeron A . Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol. 2005; 43(9):4902-4. PMC: 1234079. DOI: 10.1128/JCM.43.9.4902-4904.2005. View

10.

Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold N, Shaw K, Patterson T . Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. Antimicrob Agents Chemother. 2020; 64(6). PMC: 7269494. DOI: 10.1128/AAC.00178-20. View

11.

Mercier T, Guldentops E, Lagrou K, Maertens J . Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age. Front Microbiol. 2018; 9:661. PMC: 5893815. DOI: 10.3389/fmicb.2018.00661. View

12.

Chai L, Kullberg B, Johnson E, Teerenstra S, Khin L, Vonk A . Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012; 50(7):2330-6. PMC: 3405588. DOI: 10.1128/JCM.06513-11. View